Silva, Maria Elena and Lange, Simona and Hinrichsen, Bryan and Philp, Amber R. and Reyes, Carolina R. and Halabi, Diego and Mansilla, Josselyne B. and Rotheneichner, Peter and Guzman de la Fuente, Alerie and Couillard-Despres, Sebastien and Bátiz, Luis F. and Franklin, Robin J. M. and Aigner, Ludwig and Rivera, Francisco J. (2019) Pericytes Favor Oligodendrocyte Fate Choice in Adult Neural Stem Cells. Frontiers in Cellular Neuroscience, 13. ISSN 1662-5102
pubmed-zip/versions/2/package-entries/fncel-13-00085-r1/fncel-13-00085.pdf - Published Version
Download (3MB)
Abstract
Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS). Upon demyelination, oligodendrocyte progenitor cells (OPCs) are activated and they proliferate, migrate and differentiate into myelin-producing oligodendrocytes. Besides OPCs, neural stem cells (NSCs) may respond to demyelination and generate oligodendrocytes. We have recently shown that CNS-resident pericytes (PCs) respond to demyelination, proliferate and secrete Laminin alpha2 (Lama2) that, in turn, enhances OPC differentiation. Here, we aimed to evaluate whether PCs influence the fate choice of NSCs in vitro, towards the production of new myelin-producing cells. Indeed, upon exposure to conditioned medium derived from PCs (PC-CM), the majority of NSCs gave rise to GalC- and myelin basic protein (MBP)-expressing oligodendrocytes at the expense of the generation of GFAP-positive astrocytes. Consistent with these findings, PC-CM induces an increase in the expression of the oligodendrocyte fate determinant Olig2, while the expression level of the astrocyte determinant ID2 is decreased. Finally, pre-incubation of PC-CM with an anti-Lama2 antibody prevented the generation of oligodendrocytes. Our findings indicate that PCs-derived Lama2 instructs NSCs to an oligodendrocyte fate choice favoring the generation of myelin-producing cells at the expense of astrocytes in vitro. Further studies aiming to reveal the role of PCs during remyelination may pave the way for the development of new therapies for the treatment of MS.
Item Type: | Article |
---|---|
Subjects: | Archive Science > Medical Science |
Depositing User: | Managing Editor |
Date Deposited: | 27 May 2023 06:24 |
Last Modified: | 07 Jun 2024 10:58 |
URI: | http://editor.pacificarchive.com/id/eprint/1000 |